CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial

... Read more

U.S. FDA Removes Clinical Hold on CEL-SCI ’s Phase 3 Head & Neck Cancer

... Read more

CEL-SCI Granted European Patent for Multikine ’s Mechanism of Action in

... Read more

FDA Grants Orphan Drug Status to Cellect's ApoGraft ™ for Acute

... Read more

... Read more

Cemtrex Announces Q3 Sales of $24.7 Million, an Increase of

... Read more

Centrus Energy Corp. Reports Financial Results for the Fourth Quarter and

... Read more

Centrus Signs Contract for American Centrifuge Work in

... Read more

Centrus Signs Contract for Advancing U.S. Enrichment

... Read more

Centrus Signs $70 Million in New Nuclear Fuel Sales

... Read more